The impact of a pharmacist-managed dosage form conversion service on ciprofloxacin usage at a major Canadian teaching hospital: A pre- And post-intervention study

BMC Health Services Research

Volumn 5, Issue , 2005, Pages

  Ho, Bradley P ^a   Lau, Tim T Y ^a,b   Balen, Robert M ^a,b   Naumann, Terryn L ^a,b   Jewesson, Peter J ^b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPICILLIN; ANTIINFECTIVE AGENT; CEFAZOLIN; CEFTRIAXONE; CEFUROXIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; ERYTHROMYCIN; FLUCONAZOLE; LEVOFLOXACIN; METRONIDAZOLE; PENICILLIN G; TIMENTIN;

ADOLESCENT; ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG DOSAGE FORM; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACIST; TEACHING HOSPITAL; TIME SERIES ANALYSIS; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COST; DRUG USE; ECONOMICS; HOSPITAL PHARMACY; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRAM DEVELOPMENT; STATISTICS AND NUMERICAL DATA; THERAPEUTIC EQUIVALENCE; VERY ELDERLY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRITISH COLUMBIA; CIPROFLOXACIN; DRUG COSTS; DRUG UTILIZATION REVIEW; FEMALE; HOSPITALS, TEACHING; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; PHARMACY SERVICE, HOSPITAL; PROGRAM DEVELOPMENT; THERAPEUTIC EQUIVALENCY;

EID: 23944516308     PISSN: 14726963     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-5-48     Document Type: Article

References (25)

1. Bayer Inc: Cipro® product monograph. In Compendium of pharmaceuticals and specialties 2004: the Canadian drug reference for health professionals Edited by: Repchinsky C. Ottawa, ON Canadian Pharmacists Association; 2004:425-428.
2. Echols RM: Antimicrobial practice. The selection of appropriate dosages for intravenous ciprofloxacin. J Antimicrob Chemother 1993, 31:783-787.
3. Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH: Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 1992, 36:993-996.
4. Drugs and Therapeutics Committee: Formulary of Vancouver Hospital and Health Sciences Centre Edited by: Shalansky K, Hill S. Vancouver, BC. Vancouver Hospital and Health Sciences Centre; 2003:14.
5. Frighetto L, Martinusen SM, Mamdani F, Jewesson PJ: Ciprofloxacin use under a reserved drug and stepdown promotion program. Can J Hosp Pharm 1995, 48:35-42.
6. Frighetto L: New drug and drug products: parenteral ciprofloxacin (Cipro IV®). In Vancouver Hospital and Health Sciences Centre Drugs and Therapeutics Newsletter Vancouver, BC: Department of Pharmacy, Vancouver Hospital and Health Sciences Centre; 1992.
7. Bunz DM, Frighetto L, Gupta S, Jewesson PJ: Simple ways to promote cost containment. DICP 1990, 24:546.
8. Martinez MJ, Freire A, Castro I, Inaraja MT, Ortega A, Del Campo V, Rodriguez I, Bardan B, Morano LE, Garcia JF: Clinical and economic impact of a pharmacist-intervention to promote sequential intravenous to oral clindamycin conversion. Pharm World Sci 2000, 22:53-58.
9. Davis C: Sequential intravenous/oral ciprofloxacin as an empiric antimicrobial therapy: results of a Canadian multicenter study. Clin Ther 1994, 16:505-521.
10. Fox ER, Beckwith MC, Tyler LS: Pharmacy-administered IV to oral therapeutic interchange program: development, implementation, and cost-assessment. Hosp Pharm 2003, 38:444-452.462
11. Malfair SC, Frighetto L, Nickoloff DM, Martinusen SM, Jewesson PJ: Evaluation of the use of cefuroxime and cefuroxime axetil in an intravenous-oral stepdown program. Ann Pharmacother 1996, 30:337-342.
12. Marra CA, Frighetto L, Quaia CB, de Lemos ML, Warkentin DI, Marra F, Jewesson PJ: A new ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis. Pharmacother 2000, 20:931-940.
13. Zamin MT, Pitre MM, Conly JM: Development of an intravenousto-oral route conversion program for antimicrobial therapy at a Canadian tertiary care health facility. Ann Pharmacother 1997, 31:564-570.
14. Grasela TH Jr, Paladino JA, Schentag JJ, Huepenbecker D, Rybacki J, Purcell JB, Fiedler JB: Clinical and economic impact of oral ciprofloxacin as follow-up to parenteral antibiotics. DICP 1991, 25:857-862.
15. Drew RH: Programs promoting timely sequential antimicrobial therapy: an American perspective. J Infect 1998:3-9.
16. Hunter KA, Dormaier GK: Pharmacist-managed intravenous to oral step-down program. Clin Ther 1995, 17:534-540.
17. Kirking DM, Svinte MK, Berardi RR, Cornish LA, Chaffee BW, Ryan ML: Evaluation of direct pharmacist intervention on conversion from parenteral to oral histamine H2-receptor antagonist therapy. DICP 1991, 25:80-84.
18. Anon: Pharmacy drug monitoring service: sequential drug therapy. In Lions' Gate Hospital Policy and Procedure Manual North Vancouver, BC: Lions' Gate Hospital; 2003. C2.3
19. Maidment ID: Why use intravenous antibiotics when oral will do? The Pharmaceutical J 1998, 261:630-632.
20. Okpara AU, Maswoswe JJ, Stewart K: Criteria-based antimicrobial IV to oral conversion program. Formulary 1995, 30:343-348.
21. Ramirez JA: Antibiotic streamlining: development and justification of an antibiotic streamlining program. Pharm Pract Manag Q 1996, 16:19-34.
22. Roberts BL Jr: Decentralizing an i.v.-to-oral conversion program. Am J Health Syst Pharm 1997, 54:524-525.
23. Anon: IV to oral step-down. In St. Paul's Hospital Medication Manual Vancouver, BC: St. Paul's Hospital; 2003.
24. Wong-Beringer A, Nguyen KH, Razeghi J: Implementing a program for switching from i.v. to oral antimicrobial therapy. Am J Health Syst Pharm 2001, 58:1146-1149.
25. Anon: Drug Cost Containment Strategies. Vancouver Hospital and Health Sciences Centre Drug and Therapeutics Newsletter 2003, 10(41-3 [http://vhpharmsci.com/Newsletters/2003-NEWS/ Dec03nws.pdf]. Vancouver, BC: Pharmaceutical Sciences Clinical Services Unit, Vancouver Hospital and Health Sciences Centre